Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction

Table 2 Multivariable Cox regression analyses for the composite endpoint of all-cause mortality and readmission due to heart failure

	HR (95% CI)	p value
Composite endpoint
Stanniocalcin-2^a	2.06 (1.13–3.75)	0.018
IGFBP-4^a	1.73 (1.14–2.64)	0.010
Killip–Kimball class III–IV	1.40 (1.13–1.74)	0.002
NT-ProBNP^a	1.21 (1.07–1.37)	0.002
Age	1.06 (1.04–1.08)	< 0.001
LVEF	0.97 (0.95–0.98)	< 0.001
All-cause mortality
Stanniocalcin-2^a	2.23 (1.16–4.29)	0.017
Killip–Kimball class II–IV	1.64 (1.30–2.08)	< 0.001
NT-ProBNP^a	1.18 (1.02–1.36)	0.028
Age	1.07 (1.05–1.10)	< 0.001
LVEF	0.97 (0.95–0.99)	0.002
Readmission due to heart failure
Stanniocalcin-2^a	3.42 (1.22–9.60)	0.020
Prior myocardial infarction	2.85 (1.32–6.16)	0.008
Diabetes mellitus	2.36 (1.22–4.58)	0.011
Female sex	2.21 (1.15–4.28)	0.018
Age	1.04 (1.01–1.07)	0.005
LVEF	0.94 (0.92–0.97)	< 0.001

IGFBP-4 insulin-like growth factor binding protein-4, LVEF left ventricular ejection fraction
^aHRs (95% CIs) are reported per 1-SD increment of natural log-transformed plasma levels